Tiziana Life Sciences reports topline data from Phase 2a INFORM-MS trial of intranasal foralumab; meets dual primary endpoints

Tiziana Life Sciences announced topline data from its Phase 2a INFORM-MS trial of intranasal foralumab in patients with non-active secondary progressive MS, saying the trial met its dual primary endpoints.

Detected & updated continuously · Source: Nebula